Orteronel
Orteronel (pronounced: or-ter-o-nel) is a non-steroidal antiandrogen that was under development for the treatment of prostate cancer. It was developed by Takeda Pharmaceutical Company but its development was discontinued in 2014.
Etymology
The term "Orteronel" does not have a known etymology. It is a coined term used to represent this specific drug.
Pharmacology
Orteronel selectively inhibits 17,20-lyase, an enzyme which is necessary for the production of androgens in the body. Androgens are hormones that play a role in male traits and reproductive activity. It is these hormones that can stimulate the growth of prostate cancer cells. By inhibiting the production of these hormones, Orteronel can slow the growth of these cells.
Clinical Trials
Orteronel was studied in phase III clinical trials for the treatment of patients with metastatic, castration-resistant prostate cancer. However, the trials did not meet their primary endpoint of improved overall survival and the development of the drug was discontinued.
Related Terms
External links
- Medical encyclopedia article on Orteronel
- Wikipedia's article - Orteronel
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski